

Prof. HAKAN GÖKER

Personal Information

Email: hakan.goker@hacettepe.edu.tr

Web: <https://avesis.hacettepe.edu.tr/hakan.goker>

International Researcher IDs

ORCID: 0000-0002-1039-7756

Yoksis Researcher ID: 170556

Education Information

Post Doctorate of Medicine, Hacettepe University, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Turkey 2000 - 2000

Post Doctorate of Medicine, Hacettepe University, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Turkey 2000 - 2000

Post Doctorate of Medicine, Duke University, Onkoloji Ve Kemik İliği Nakli, United States Of America 1996 - 1999

Post Doctorate of Medicine, University of Illinois at Chicago, Hematoloji Ve Onkoloji, United States Of America 1996 - 1999

Expertise In Medicine, Hacettepe University, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Turkey 1988 - 1992

Foreign Languages

English, C1 Advanced

Research Areas

Health Sciences

Academic Titles / Tasks

Professor, Hacettepe University, Tıp Fakültesi (Türkçe), Dahili Tıp Bilimleri Bölümü, 2009 - Continues

Associate Professor, Hacettepe University, Tıp Fakültesi (İngilizce), Dahili Tıp Bilimleri Bölümü, 2003 - 2009

Lecturer, Hacettepe University, Tıp Fakültesi (İngilizce), Dahili Tıp Bilimleri Bölümü, 2000 - 2003

Academic and Administrative Experience

Hacettepe Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, 2013 - 2015

Published journal articles indexed by SCI, SSCI, and AHCI

- Long-Term Outcomes of Allogeneic Stem Cell Transplantation for Relapsed/Refractory Hodgkin and Non-Hodgkin Lymphoma: Multi-center Experience from Turkey**
Uysal A., SOYER N., Ozdogu H., GÖKER H., ÇINAR O. E., Devenci B., YILMAZ A. F., ATAGÜNDÜZ I., Tekgunduz A. I. E., İZMİR GÜNER Ş., et al.

INDIAN JOURNAL OF HEMATOLOGY AND BLOOD TRANSFUSION, 2024 (SCI-Expanded)

- II. **Asymptomatic unilateral phrenic nerve palsy after bortezomib treatment in a newly diagnosed multiple myeloma patient**
Coskunpinar M., Erdogdu B., GÖKER H.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE, vol.29, no.2, pp.502-505, 2023 (SCI-Expanded)
- III. **Hypophosphatemia related to the use of ibrutinib**
KARADENİZ M., ÇINAR O. E., Erdogdu B., MALKAN Ü. Y., GÖKER H., ÖZCEBE O. İ.
Journal of Oncology Pharmacy Practice, 2023 (SCI-Expanded)
- IV. **A single-center experience of haploidentical stem cell transplantation in hematological malignancies**
MALKAN Ü. Y., GÖKER H., DEMİROĞLU H., Tekin F., Akdemir B., ALADAĞ KARAKULAK E., SAYINALP N., HAZNEDAROĞLU İ. C., ÖZCEBE O. İ., BÜYÜKAŞIK Y.
Turkish Journal of Medical Sciences, vol.53, no.1, pp.352-359, 2023 (SCI-Expanded)
- V. **Comment on Zamfir et al. Hematologic Malignancies Diagnosed in the Context of the mRNA COVID-19 Vaccination Campaign: A Report of Two Cases. Medicina 2022, 58, 874**
ÇINAR O. E., Erdogdu B., KARADENİZ M., ÜNAL S., MALKAN Ü. Y., GÖKER H., HAZNEDAROĞLU İ. C.
MEDICINA-LITHUANIA, vol.58, no.11, 2022 (SCI-Expanded)
- VI. **Validity and reliability of the Turkish version of the functional assessment of cancer therapy-bone marrow transplant (FACT-BMT) quality of life questionnaire in patients undergoing bone marrow transplantation**
YILDIZ KABAK V., Demircioglu A., Aladag E., KARAHAN S., GÖKER H., ATASAVUN UYSAL S., DÜĞER T.
Palliative and Supportive Care, vol.20, no.4, pp.556-563, 2022 (SSCI)
- VII. **Hepatitis E Virus Prevalence and Associated Risk Factors in High-Risk Groups: A Cross-Sectional Study**
BALABAN H. Y., ASLAN A. T., AKDOĞAN KITTANA F. N., ALP A., DAĞ O., AYAR Ş. N., Vahabov C., ŞİMŞEK C., YILDIRIM T., GÖKER H., et al.
TURKISH JOURNAL OF GASTROENTEROLOGY, vol.33, no.7, pp.615-624, 2022 (SCI-Expanded)
- VIII. **Prospective registry of adult patients receiving therapeutic plasma exchange with a presumptive diagnosis of thrombotic microangiopathy (TMA): The Turkish hematology research and education group (ThREG)-TMA02 study**
Akpınar S., Tekgunduz E., Esen R., YILMAZ M., Karakus V., VURAL F., Gediz F., AYDOĞDU İ., KAYNAR L., GÖKER H., et al.
TRANSFUSION AND APHERESIS SCIENCE, vol.61, no.1, 2022 (SCI-Expanded)
- IX. **Hematopoietic Adverse Events Associated with BNT162b2 mRNA Covid-19 Vaccine**
Erdogdu B., ÇINAR O. E., Malkan Ü. Y., AKSU S., DEMİROĞLU H., BÜYÜKAŞIK Y., GÖKER H., SAYINALP N., HAZNEDAROĞLU İ. C.
UHOD-ULUSLARARASI HEMATOLOJİ-ONKOLOJİ DERGİSİ, vol.32, no.1, pp.65-67, 2022 (SCI-Expanded)
- X. **Efficacy of eltrombopag in thrombocytopenia after hematopoietic stem cell transplantation**
KARATAŞ A., GÖKER H., DEMİROĞLU H., MALKAN Ü. Y., Velet M., ÇINAR O. E., Erdogdu B., KARADENİZ M., SAYINALP N., AKSU S., et al.
TURKISH JOURNAL OF MEDICAL SCIENCES, vol.52, no.2, pp.413-419, 2022 (SCI-Expanded)
- XI. **Covid-19 Related Fatality and Risk Factors in Multiple Myeloma: A Multicenter Cohort Study**
KARADENİZ M., GÖKER H., Aydın O., Turgut M., MALKAN Ü. Y., Sener E., Erdogdu B., ÇINAR O. E., HAZNEDAROĞLU İ. C., SAYINALP N., et al.
UHOD - Uluslararası Hematoloji-Onkoloji Dergisi, vol.32, no.4, pp.209-213, 2022 (SCI-Expanded)
- XII. **Long-term results of allogeneic peripheral blood hematopoietic stem cell transplantation for severe aplastic anemia**
ALADAĞ KARAKULAK E., GÖKER H., DEMİROĞLU H., AKSU S., SAYINALP N., HAZNEDAROĞLU İ. C., ÖZCEBE O. İ., BÜYÜKAŞIK Y.
TRANSFUSION AND APHERESIS SCIENCE, vol.60, no.2, 2021 (SCI-Expanded)
- XIII. **Allogeneic Hematopoietic Stem-Cell Transplantation Improves Disease-Free Survival Compared to Pediatric-Inspired Berlin-Frankfurt-Munster Chemotherapy in Adult Acute Lymphoblastic Leukemia**

ALADAĞ KARAKULAK E., Aktimur S. H., Aydin O., DEMİROĞLU H., BÜYÜKAŞIK Y., AKSU S., ÖZCEBE O. İ., HAZNEDAROĞLU İ. C., SAYINALP N., Turgut M., et al.

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, vol.21, no.3, pp.147-153, 2021 (SCI-Expanded)

- XIV. **Four-Dimensional Echocardiographic Evaluation of Left Ventricular Systolic Functions in Patients with Chronic Myeloid Leukaemia Receiving Tyrosine Kinase Inhibitors**
KARAKULAK U. N., ALADAĞ KARAKULAK E., HEKİMSOY V., ŞAHİNER M. L., KAYA E. B., ÖZER N., AKSU S., DEMİROĞLU H., GÖKER H., BÜYÜKAŞIK Y., et al.
CARDIOVASCULAR TOXICOLOGY, vol.21, no.3, pp.216-223, 2021 (SCI-Expanded)
- XV. **Comparison of single and double autologous stem cell transplantation in multiple myeloma patients**
Malkan Ü. Y., DEMİROĞLU H., BÜYÜKAŞIK Y., KARATAŞ A., ALADAĞ KARAKULAK E., GÖKER H.
OPEN MEDICINE, vol.16, no.1, pp.192-197, 2021 (SCI-Expanded)
- XVI. **Central nervous system involvement in patients with acute myeloid leukemia**
YAŞAR H. A., ÇINAR O. E., Koylu N. Y., BARIŞTA İ., GÖKER H., BÜYÜKAŞIK Y.
TURKISH JOURNAL OF MEDICAL SCIENCES, vol.51, no.5, pp.2351-2356, 2021 (SCI-Expanded)
- XVII. **Effect of Salvage Chemotherapy Before Donor Lymphocyte Infusion in Patients With Relapse After Allogeneic Hematologic Stem Cell Transplantation**
ALADAĞ KARAKULAK E., GÖKER H., BÜYÜKAŞIK Y., DEMİROĞLU H.
TRANSPLANTATION PROCEEDINGS, vol.53, no.1, pp.391-395, 2021 (SCI-Expanded)
- XVIII. **Comparison of Risk Scoring Systems in HLA-Matched Related Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective Cohort Study**
ALADAĞ KARAKULAK E., DEMİROĞLU H., BÜYÜKAŞIK Y., GÖKER H.
TURKISH JOURNAL OF HEMATOLOGY, vol.38, no.2, pp.138-144, 2021 (SCI-Expanded)
- XIX. **Prediction of Stem Cell Mobilization Failure in Patients with Hodgkin and Non-Hodgkin Lymphoma**
DEMİROĞLU H., Ciftçiler R., BÜYÜKAŞIK Y., GÖKER H.
TURKISH JOURNAL OF HEMATOLOGY, vol.38, no.3, pp.204-210, 2021 (SCI-Expanded)
- XX. **Hematopoietic Stem Cell Transplantation for Patients with Paroxysmal Nocturnal Hemoglobinuria with or without Aplastic Anemia: A Multicenter Turkish Experience**
Yilmaz F., SOYER N., Seval G. C., Bozdogan S. C., TOPÇUOĞLU P., ÜNAL A., KAYNAR L., Ozgur G., Sucak G., GÖKER H., et al.
TURKISH JOURNAL OF HEMATOLOGY, vol.38, no.3, pp.195-203, 2021 (SCI-Expanded)
- XXI. **Assessment of ST2 and Reg3a levels in patients with acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation**
ALADAĞ KARAKULAK E., DEMİROĞLU H., Malkan Ü. Y., Akman U., GÖKER H., BÜYÜKAŞIK Y.
TURKISH JOURNAL OF MEDICAL SCIENCES, vol.51, no.1, pp.355-358, 2021 (SCI-Expanded)
- XXII. **Evaluation of Prognostic Significance of the International Staging System According to Glomerular Filtration Rate in Newly Diagnosed Multiple Myeloma Patients Eligible for Autologous Stem Cell Transplantation**
Ciftçiler R., GÖKER H., DEMİROĞLU H., HAZNEDAROĞLU İ. C., SAYINALP N., AKSU S., Ozcebe O., BÜYÜKAŞIK Y.
TURKISH JOURNAL OF HEMATOLOGY, vol.38, no.1, pp.33-40, 2021 (SCI-Expanded)
- XXIII. **Effects of partly supervised and home-based exercise program in patients undergoing hematopoietic stem cell transplantation: a case-control study**
YILDIZ KABAK V., GÖKER H., DÜGER T.
SUPPORTIVE CARE IN CANCER, vol.28, no.12, pp.5851-5860, 2020 (SCI-Expanded)
- XXIV. **Prolonged viral shedding in a lymphoma patient with COVID-19 infection receiving convalescent plasma**
KARATAŞ A., İNKAYA A. Ç., DEMİROĞLU H., AKSU S., Haziyevev T., ÇINAR O. E., ALP A., UZUN Ö., SAYINALP N., GÖKER H.
Transfusion and Apheresis Science, vol.59, no.5, 2020 (SCI-Expanded)
- XXV. **Early Access Program Results From Turkey and a Literature Review on Daratumumab Monotherapy Among Heavily Pretreated Patients With Relapsed/Refractory Myeloma**
BEKSAÇ M., Aydin Y., GÖKER H., Turgut M., Besisik S. K., Cagirgan S., Tuğlular T., VURAL F., Yagci M., ALACACIOĞLU

İ., et al.

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, vol.20, no.8, 2020 (SCI-Expanded)

- XXVI. **Incidence and risk factors for hepatic sinusoidal obstruction syndrome after allogeneic hematopoietic stem cell transplantation: A retrospective multicenter study of Turkish hematology research and education group (ThREG)**
SOYER N., Gunduz M., Tekgunduz E., Devenci B., Ozdogu H., ŞAHİN H. H., ERMİŞ TURAK E., OKAY M., KUKU İ., Hindilerden I. Y., et al.
TRANSFUSION AND APHERESIS SCIENCE, vol.59, no.4, 2020 (SCI-Expanded)
- XXVII. **Cardiac adverse events during stem cell transplantation for hematological malignancies: A single centre experience**
ALADAĞ KARAKULAK E., DEMİROĞLU H., BÜYÜKAŞIK Y., KARAKULAK U. N., Tekin F., AKSU S., GÖKER H.
TRANSFUSION AND APHERESIS SCIENCE, vol.59, no.2, 2020 (SCI-Expanded)
- XXVIII. **Richter's transformation in patients with chronic lymphocytic leukemia: a cohort study about risk factors**
OKAY M., GÜNEŞ G., Malkan Ü. Y., Heziyev T., GÖKER H., HAZNEDAROĞLU İ. C., Ozcebe O., SAYINALP N.
LEUKEMIA & LYMPHOMA, vol.61, pp.50-52, 2020 (SCI-Expanded)
- XXIX. **Impact of ABO blood group incompatibility on the outcomes of allogeneic hematopoietic stem cell transplantation**
Ciftciler R., GÖKER H., BÜYÜKAŞIK Y., KARAAĞAÇ AKYOL T., AKSU S., Tekin F., DEMİROĞLU H.
TRANSFUSION AND APHERESIS SCIENCE, vol.59, no.1, 2020 (SCI-Expanded)
- XXX. **Predictive factors for stem cell mobilization failure in multiple myeloma patients: A single center experience**
GÖKER H., Ciftciler R., DEMİROĞLU H., Turgut M., SAYINALP N., Haznedaroglu I. C., OKAY M., Tekin F., BÜYÜKAŞIK Y.
TRANSFUSION AND APHERESIS SCIENCE, vol.59, no.1, 2020 (SCI-Expanded)
- XXXI. **Long-term results of brentuximab vedotin in relapsed and refractory Hodgkin lymphoma: multi-center real-life experience**
Ozbalak M., SALİHOĞLU A., Soysal T., Karadogan I., PAYDAŞ S., Ozdemir E., Yildiz B., Karadurmus N., KAYNAR L., Yagci M., et al.
ANNALS OF HEMATOLOGY, vol.99, no.2, pp.301-307, 2020 (SCI-Expanded)
- XXXII. **The experience of allogeneic hematopoietic stem cell transplantation in a patient with X-linked adrenoleukodystrophy**
Ciftciler R., GÖKER H., BÜYÜKAŞIK Y., TOPÇU M., Gevher N., DEMİROĞLU H.
TRANSFUSION AND APHERESIS SCIENCE, vol.59, no.1, 2020 (SCI-Expanded)
- XXXIII. **The comparison of bone marrow kinetics between patients with acute myeloid leukemia and acute promyelocytic leukemia after induction chemotherapy**
Ciftciler R., HAZNEDAROĞLU İ. C., Ozcebe O., AKSU S., SAYINALP N., GÖKER H., DEMİROĞLU H., BÜYÜKAŞIK Y.
IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY, vol.42, no.1, pp.17-21, 2020 (SCI-Expanded)
- XXXIV. **Acute Graft-Versus-Host Disease: A Brief Review**
ALADAĞ KARAKULAK E., KELKİTLİ E., GÖKER H.
TURKISH JOURNAL OF HEMATOLOGY, vol.37, no.1, pp.1-4, 2020 (SCI-Expanded)
- XXXV. **The Impact of Early Versus Late Platelet and Neutrophil Recovery after Induction Chemotherapy on Survival Outcomes of Patients with Acute Myeloid Leukemia**
Ciftciler R., HAZNEDAROĞLU İ. C., SAYINALP N., Ozcebe O., AKSU S., DEMİROĞLU H., GÖKER H., Malkan Ü. Y., BÜYÜKAŞIK Y.
TURKISH JOURNAL OF HEMATOLOGY, vol.37, no.2, pp.116-120, 2020 (SCI-Expanded)
- XXXVI. **Evaluation of the Survival Outcomes of Multiple Myeloma Patients According to Their Plasmacytoma Presentation at Diagnosis**
Ciftciler R., GÖKER H., DEMİROĞLU H., AKSU S., SAYINALP N., HAZNEDAROĞLU İ. C., Malkan Ü. Y., BÜYÜKAŞIK Y., Ozcebe O.
TURKISH JOURNAL OF HEMATOLOGY, vol.37, no.4, pp.256-262, 2020 (SCI-Expanded)
- XXXVII. **What is the role of the decrease in immunoglobulin level after the first cycle in patient with multiple**

myeloma?

GÖKER H., KELKİTLİ E., Turgut M.

AMERICAN JOURNAL OF HEMATOLOGY, vol.94, 2019 (SCI-Expanded)

XXXVIII. **SECONDARY MALIGNANCIES IN PATIENTS WITH MULTIPLE MYELOMA**

ALADAĞ KARAKULAK E., BÜYÜKAŞIK Y., DEMİROĞLU H., AKSU S., GÖKER H.

AMERICAN JOURNAL OF HEMATOLOGY, vol.94, 2019 (SCI-Expanded)

XXXIX. **Impact of Time Between Induction Chemotherapy and Complete Remission on Survival Outcomes in Patients With Acute Myeloid Leukemia**

Ciftçiler R., DEMİROĞLU H., HAZNEDAROĞLU İ. C., SAYINALP N., AKSU S., Ozcebe O., GÖKER H., Aydın M. S., BÜYÜKAŞIK Y.

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, vol.19, no.11, pp.729-734, 2019 (SCI-Expanded)

XL. **Elotuzumab Plus Pomalidomide or Lenalidomide is Able to Achieve Durable \geq Vgpr Responses Among Immunomodulatory/Proteasome Inhibitor Refractory Myeloma Patients: A Report on Multicenter Experience From Turkey**

BEKSAÇ M., Seval G. C., PAYDAŞ S., Tuğlular T. F., ARSLAN Ö., GÖKER H., KAYNAR L., ALTUNTAŞ F., Atalay F., Teke H. U., et al.

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, vol.19, no.10, 2019 (SCI-Expanded)

XLI. **Impact of Pre-transplant and Post-transplant Remission Status of Patients on Survival in Newly Diagnosed Multiple Myeloma**

Ciftçiler R., GÖKER H., BÜYÜKAŞIK Y., ALADAĞ KARAKULAK E., DEMİROĞLU H.

INDIAN JOURNAL OF HEMATOLOGY AND BLOOD TRANSFUSION, vol.35, no.4, pp.655-661, 2019 (SCI-Expanded)

XLII. **Mantle cell lymphoma: a Turkish Multi-Center Study**

OKAY M., MELETLİ Ö., KELKİTLİ E., Malkan Ü. Y., Turgut M., BÜYÜKAŞIK Y., Tekin F., DEMİROĞLU H., GÖKER H.

JOURNAL OF BUON, vol.24, no.5, pp.2084-2089, 2019 (SCI-Expanded)

XLIII. **Impact of bone marrow plasma cells percentage on survival at diagnosis and pre-transplant period in newly diagnosed multiple myeloma: Experience of a single center from Turkey**

Ciftçiler R., GÖKER H., BÜYÜKAŞIK Y., ALADAĞ KARAKULAK E., Sağlam E. A., DEMİROĞLU H.

TRANSFUSION AND APHERESIS SCIENCE, vol.58, no.3, pp.313-317, 2019 (SCI-Expanded)

XLIV. **Extramedullary relapses of acute leukemias after allogeneic hematopoietic stem cell transplantation: clinical features, cumulative incidence, and risk factors**

Gunes G., GÖKER H., DEMİROĞLU H., Malkan Ü. Y., BÜYÜKAŞIK Y.

BONE MARROW TRANSPLANTATION, vol.54, no.4, pp.595-600, 2019 (SCI-Expanded)

XLV. **Efficacy and Feasibility of Allogeneic Hematopoietic Stem-Cell Transplantation in the Treatment of Refractory Acute Myeloid Leukemia**

Ciftçiler R., DEMİROĞLU H., BÜYÜKAŞIK Y., ALADAĞ KARAKULAK E., AKSU S., HAZNEDAROĞLU İ. C., SAYINALP N., Ozcebe O., Malkan Ü. Y., GÖKER H.

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, vol.19, no.3, pp.177-182, 2019 (SCI-Expanded)

XLVI. **Unclassifiable non-CML classical myeloproliferative diseases with microcytosis: findings indicating diagnosis of polycythemia vera masked by iron deficiency**

ALADAĞ KARAKULAK E., AKSU S., DEMİROĞLU H., SAYINALP N., GÖKER H., HAZNEDAROĞLU İ. C., ÖZCEBE O. İ., BÜYÜKAŞIK Y.

TURKISH JOURNAL OF MEDICAL SCIENCES, vol.49, no.5, pp.1560-1563, 2019 (SCI-Expanded)

XLVII. **Impact of pre-transplant bone marrow blast percentage on survival in acute myeloid leukemia patients**

Ciftçiler R., GÖKER H., BÜYÜKAŞIK Y., Malkan Ü. Y., Sağlam E. A., DEMİROĞLU H.

INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, vol.12, no.7, pp.9288-9294, 2019 (SCI-Expanded)

XLVIII. **Comparison of Myeloablative Versus Reduced-Intensity Conditioning Regimens for Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia: A Cohort Study**

Ciftçiler R., GÖKER H., DEMİROĞLU H., ALADAĞ KARAKULAK E., AKSU S., HAZNEDAROĞLU İ. C., SAYINALP N., Ozcebe O., Tekin F., BÜYÜKAŞIK Y.

TURKISH JOURNAL OF HEMATOLOGY, vol.36, no.2, pp.88-96, 2019 (SCI-Expanded)

- XLIX. **Mitoxantrone-melphalan conditioning regimen for autologous stem cell transplantation in relapsed/refractory lymphoma**
OKAY M., BÜYÜKAŞIK Y., DEMİROĞLU H., Malkan Ü. Y., Ciftciler R., ALADAĞ KARAKULAK E., AKSU S., HAZNEDAROĞLU İ. C., SAYINALP N., ÖZCEBE O. İ., et al.
TURKISH JOURNAL OF MEDICAL SCIENCES, vol.49, no.4, pp.985-992, 2019 (SCI-Expanded)
- L. **Effect of postremission high dose cytarabine-based consolidation chemotherapy before allogeneic stem cell transplantation in outcomes of acute myeloid leukemia patients**
CIFTCILER R., DEMİROĞLU H., BÜYÜKAŞIK Y., OKAY M., AKSU S., Sayinalp N., MALKAN Ü. Y., HAZNEDAROĞLU İ. C., Ozcebe O., GÖKER H.
TRANSFUSION AND APHERESIS SCIENCE, vol.57, no.6, pp.752-755, 2018 (SCI-Expanded)
- LI. **Hematopoietic stem cell transplantation in geriatric patients in Turkey**
GÖKER H., KELKİTLİ E., BÜYÜKAŞIK Y., DEMİROĞLU H.
TRANSFUSION AND APHERESIS SCIENCE, vol.57, no.2, pp.159-162, 2018 (SCI-Expanded)
- LII. **Pediatric Chemotherapeutic Regimen (BFM-95) is Superior for Overall Survival in Adult Acute Lymphoblastic Leukemia**
KARCIOĞLU A. M., OKAY M., BÜYÜKAŞIK Y., Malkan Ü. Y., SAYINALP N., DEMİROĞLU H., GÖKER H., AKSU S., ÖZCEBE O. İ., HAZNEDAROĞLU İ. C.
UHOD-ULUSLARARASI HEMATOLOJİ-ONKOLOJİ DERGİSİ, vol.28, no.4, pp.254-260, 2018 (SCI-Expanded)
- LIII. **Biosimilar filgrastim (leucostim (R)) have similar efficacy in steady-state hematopoietic progenitor cell mobilization compared to original filgrastim (neupogen (R)) and lenograstim (granocyte (R)): A retrospective multicenter study**
Kayıkcı O., Tekgunduz E., Kaya A. H., GÖKER H., Aslan A., Iskender D., Namdaroglu S., Tetik A., Kocubaba S., Altuntas F.
TRANSFUSION AND APHERESIS SCIENCE, vol.56, no.6, pp.832-835, 2017 (SCI-Expanded)
- LIV. **Current practice of autologous hematopoietic progenitor cell mobilization in adult patients with multiple myeloma and lymphoma: The results of a survey from Turkish hematology research and education group (ThREG)**
Tekgunduz E., DEMİRKAN F., VURAL F., GÖKER H., Ozdogu H., KİKİ İ., AYDOĞDU İ., KAYNAR L., ERKURT M. A., Cagırgan S., et al.
TRANSFUSION AND APHERESIS SCIENCE, vol.56, no.6, pp.804-808, 2017 (SCI-Expanded)
- LV. **Autologous hematopoietic progenitor cell mobilization and collection in adult patients presenting with multiple myeloma and lymphoma: A position-statement from the Turkish Society of Apheresis (TSA)**
Tekgunduz E., Arat M., GÖKER H., Ozdogu H., KAYNAR L., Cagırgan S., ERKURT M. A., VURAL F., KİKİ İ., Altuntas F., et al.
TRANSFUSION AND APHERESIS SCIENCE, vol.56, no.6, pp.845-849, 2017 (SCI-Expanded)
- LVI. **Sole Infrequent Karyotypic Aberration Trisomy 6 in a Patient with Acute Myeloid Leukemia and Breast Cancer in Remission**
AYDIN M. S., BOZKURT S., GÜNEŞ G., Malkan Ü. Y., Aslan T., ETGÜL S., BÜYÜKAŞIK Y., HAZNEDAROĞLU İ. C., SAYINALP N., GÖKER H., et al.
TURKISH JOURNAL OF HEMATOLOGY, vol.34, no.1, pp.103-104, 2017 (SCI-Expanded)
- LVII. **Reversible diffusion restriction of optic radiations: A distinct form of cyclosporine induced leukoencephalopathy presenting with visual loss**
GÖÇMEN R., Colpak A. I., GÖKER H., Kaya A. A., Onder H.
JOURNAL OF THE NEUROLOGICAL SCIENCES, vol.366, pp.155-157, 2016 (SCI-Expanded)
- LVIII. **Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia in Daily Practice: A Multicenter Experience**
Tekgunduz E., GÖKER H., KAYNAR L., SARI İ., Pala C., Dogu M. H., Ozturk E., TURGUT B., KORKMAZ S., Tetik A., et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, vol.16, no.5, pp.269-274, 2016 (SCI-Expanded)
- LIX. **Association of Macroeconomic Factors With Nonrelapse Mortality After Allogeneic Hematopoietic**

Cell Transplantation for Adults With Acute Lymphoblastic Leukemia: An Analysis From the Acute Leukemia Working Party of the EBMT

Giebel S, Labopin M, Ibatci A, Browne P, Czerw T, Socie G, ÜNAL A, Kyrzcz-Krzemien S, Bacigalupo A, GÖKER H, et al.

ONCOLOGIST, vol.21, no.3, pp.377-383, 2016 (SCI-Expanded)

- LX. **Chimeric antigen receptor T cell treatment in hematologic malignancies**
GÖKER H, Malkan Ü. Y., DEMİROĞLU H., BÜYÜKAŞIK Y.
TRANSFUSION AND APHERESIS SCIENCE, vol.54, no.1, pp.35-40, 2016 (SCI-Expanded)
- LXI. **Retrospective analysis of adult patients with acute lymphoblastic leukemia undergoing allogeneic hematopoietic cell transplantation: A multicenter experience of daily practice**
Tekgunduz E., KAYNAR L., GÖKER H., Kaya A. H., ERMİŞ TURAK E., ELİAÇIK E., Kayikci O., ÇETİN M., BÜYÜKAŞIK Y., ESER B., et al.
TRANSFUSION AND APHERESIS SCIENCE, vol.54, no.1, pp.41-47, 2016 (SCI-Expanded)
- LXII. **Hematopoietic cell transplantation activity of Turkey in 2014: Ongoing increase in HCT rates**
Tekgunduz E., Sencan I., Kapuagasi A., Unal D., Ozturk M., Gumus E., GÖKER H., TAVİL E. B., ERTEM M., ÇETİN M., et al.
TRANSFUSION AND APHERESIS SCIENCE, vol.54, no.1, pp.53-59, 2016 (SCI-Expanded)
- LXIII. **The Impact of Iron Overload on Transplant-Related Complications and Prognosis of Acute Leukemias**
Malkan U. Y., GÜNEŞ G., ELİAÇIK E., HAZNEDAROĞLU İ. C., Yayar O., ETGÜL S., Aslan T., Aydin S., GÖKER H., DEMİROĞLU H., et al.
UHOD-ULUSLARARASI HEMATOLOJİ-ONKOLOJİ DERGİSİ, vol.26, no.1, pp.54-60, 2016 (SCI-Expanded)
- LXIV. **Idelalisib at the Crossroads of B-Cell Lymphoproliferative Disorders**
AKSU S., Ayyıldız O., ETGÜL S., GÖKER H., GÜNEŞ G., HAZNEDAROĞLU İ. C., İLHAN O., Kaynar L. G., Malkan U. Y., ÖZDEMİR E., et al.
UHOD-ULUSLARARASI HEMATOLOJİ-ONKOLOJİ DERGİSİ, vol.26, no.1, pp.12-19, 2016 (SCI-Expanded)
- LXV. **Comparison of Myelodysplastic Syndrome Prognostic Scoring Systems**
BEKTAŞ Ö., ÜNER A., ELİAÇIK E., Uz B., Isik A., ETGÜL S., BOZKURT S., HAZNEDAROĞLU İ. C., GÖKER H., SAYINALP N., et al.
TURKISH JOURNAL OF HEMATOLOGY, vol.33, no.2, pp.119-126, 2016 (SCI-Expanded)
- LXVI. **The Impact of Jak1/Jak2 Inhibitor Ruxolitinib on the Spleen Size and Symptom Burden in Myeloproliferative Diseases**
Aktimur S. H., Malkan U. Y., Eyupoglu D. N., HAZNEDAROĞLU İ. C., KELKİTLİ E., Atay H. M., GÜNEŞ G., ETGÜL S., Aslan T., GÖKER H., et al.
UHOD-ULUSLARARASI HEMATOLOJİ-ONKOLOJİ DERGİSİ, vol.26, no.3, pp.153-158, 2016 (SCI-Expanded)
- LXVII. **The Prognosis of Adult Burkitt's Cell Leukemia in Real-Life Clinical Practice**
Malkan Ü. Y., GÜNEŞ G., GÖKER H., HAZNEDAROĞLU İ. C., Acar K., ELİAÇIK E., ETGÜL S., Aslan T., Balaban S., DEMİROĞLU H., et al.
TURKISH JOURNAL OF HEMATOLOGY, vol.33, no.4, pp.281-285, 2016 (SCI-Expanded)
- LXVIII. **High frequency of autonomous T-cell proliferation compatible with T-cell large granular lymphocytic leukemia in patients with cytopenia of unknown etiology**
BEKTAŞ Ö., ÜNER A., Aydin S. M., ELİAÇIK E., Uz B., Isik A., HAZNEDAROĞLU İ. C., GÖKER H., SAYINALP N., AKSU S., et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY, vol.102, no.2, pp.211-217, 2015 (SCI-Expanded)
- LXIX. **Bone marrow fibrosis may be an effective independent predictor of the 'TKI drug response level' in chronic myeloid leukemia**
ELİAÇIK E., Isik A., Aydin C., ÜNER A., AKSU S., SAYINALP N., DEMİROĞLU H., GÖKER H., BÜYÜKAŞIK Y., Ozcebe O., et al.
HEMATOLOGY, vol.20, no.7, pp.392-396, 2015 (SCI-Expanded)
- LXX. **Optimizing mobilization strategies in difficult-to-mobilize patients: The role of plerixafor**
GÖKER H., ETGÜL S., BÜYÜKAŞIK Y.
TRANSFUSION AND APHERESIS SCIENCE, vol.53, no.1, pp.23-29, 2015 (SCI-Expanded)

- LXXI. **Brentuximab vedotin for relapsed or refractory Hodgkin lymphoma: experience in Turkey**
Salihoglu A., Elverdi T., KARADOĞAN I., PAYDAŞ S., ÖZDEMİR E., ERDEM G., KARADURMUS N., AKYOL G., KAYNAR L., Yegin Z. A., et al.
ANNALS OF HEMATOLOGY, vol.94, no.3, pp.415-420, 2015 (SCI-Expanded)
- LXXII. **Pharmacobiological Approach for the Clinical Development of Ruxolitinib in Myeloproliferative Neoplasms**
ELİAÇIK E., Isik A., AKSU S., ÜNER A., BÜYÜKAŞIK Y., SAYINALP N., GÖKER H., ÖZCEBE O. İ., HAZNEDAROĞLU İ. C.
TURKISH JOURNAL OF HEMATOLOGY, vol.32, no.2, pp.163-167, 2015 (SCI-Expanded)
- LXXIII. **Generic Imatinib Mesylate is as Effective as Original Glivec in the Clinical Management of CML**
Malkan Ü. Y., AKSU S., Aktimur S. H., Atay H., Bektas O., BÜYÜKAŞIK Y., DEMİROĞLU H., Eliacik E., EŞME M., Hacıhanefioglu A., et al.
UHOD-ULUSLARARASI HEMATOLOJİ-ONKOLOJİ DERGİSİ, vol.25, no.4, pp.215-221, 2015 (SCI-Expanded)
- LXXIV. **The factors affecting early death after the initial therapy of acute myeloid leukemia**
Malkan Ü. Y., GÜNEŞ G., ELİAÇIK E., HAZNEDAROĞLU İ. C., ETGÜL S., Aslan T., Yayar O., Aydin S., DEMİROĞLU H., ÖZCEBE O. İ., et al.
INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, vol.8, no.12, pp.22564-22569, 2015 (SCI-Expanded)
- LXXV. **Clinicopathological associations of acquired erythroblastopenia**
GÜNEŞ G., Malkan Ü. Y., YAŞAR H. A., ELİAÇIK E., HAZNEDAROĞLU İ. C., DEMİROĞLU H., SAYINALP N., AKSU S., ETGÜL S., Aslan T., et al.
INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, vol.8, no.12, pp.22515-22519, 2015 (SCI-Expanded)
- LXXVI. **Rebound Thrombocytosis following Induction Chemotherapy Is an Independent Predictor of a Good Prognosis in Acute Myeloid Leukemia Patients Attaining First Complete Remission**
Malkan Ü. Y., Gunes G., Isik A., Eliacik E., Etgul S., Aslan T., Balaban M. S., Haznedaroglu I. C., Demiroglu H., Goker H., et al.
ACTA HAEMATOLOGICA, vol.134, no.1, pp.32-37, 2015 (SCI-Expanded)
- LXXVII. **Massive Life-Threatening Hemorrhages Due to Toxic Oral Intake of 3750 Mg Dabigatran Etexilate As a Suicide Attempt and the Clinical Management**
GÜNEŞ G., Malkan Ü. Y., AKSU S., HAZNEDAROĞLU İ. C., BÜYÜKAŞIK Y., SAYINALP N., ÖZCEBE O. İ., GÖKER H., DEMİROĞLU H.
BLOOD, vol.124, no.21, 2014 (SCI-Expanded)
- LXXVIII. **Rebound Thrombocytosis Is an Independent Predictor of Good Prognosis in AML Patients Attaining First Complete Remission**
Malkan Ü. Y., GÜNEŞ G., GÖKER H., ELİAÇIK E., Isik A., SAYINALP N., HAZNEDAROĞLU İ. C., DEMİROĞLU H., AKSU S., ÖZCEBE O. İ., et al.
BLOOD, vol.124, no.21, 2014 (SCI-Expanded)
- LXXIX. **Local Renin-Angiotensin System in Normal Hematopoietic and Multiple Myeloma-Related Progenitor Cells**
Uz B., Tatonyan S. C., Sayitoglu M., Erbilgin Y., Hatirnaz O., AKSU S., BÜYÜKAŞIK Y., SAYINALP N., GÖKER H., ÖZCEBE O. İ., et al.
TURKISH JOURNAL OF HEMATOLOGY, vol.31, no.2, pp.136-142, 2014 (SCI-Expanded)
- LXXX. **Impact of Postremission Consolidation Chemotherapy on Outcome After Reduced-Intensity Conditioning Allogeneic Stem Cell Transplantation for Patients With Acute Myeloid Leukemia in First Complete Remission**
Yeshurun M., Labopin M., Blaise D., Cornelissen J. J., Sengeloev H., Vindelov L., Kuball J., Chevallier P., Craddock C., Socie G., et al.
CANCER, vol.120, no.6, pp.855-863, 2014 (SCI-Expanded)
- LXXXI. **Vitamin B-12 Deficiency with the Absence of Anemia in Young and Middle-Aged Population**
Kara A., Eliacik E., BÜYÜKAŞIK Y., ÖZCEBE O. İ., Haznedaroglu I., AKSU S., Bektas O., GÖKER H., Sayinali N.
UHOD-ULUSLARARASI HEMATOLOJİ-ONKOLOJİ DERGİSİ, vol.24, no.3, pp.190-194, 2014 (SCI-Expanded)

- LXXXII. **Ibrutinib: From Molecule to Medicine**
Ayyıldız O, Demirkan F, GÖKER H, HAZNEDAROĞLU İ. C., İlhan O, KAYNAR L, Ozdemir E, SAYDAM G., SAYINALP N., ŞAHİN F., et al.
UHOD-ULUSLARARASI HEMATOLOJİ-ONKOLOJİ DERGİSİ, vol.24, no.3, pp.4-14, 2014 (SCI-Expanded)
- LXXXIII. **Acute in Vitro effects of ABS (Ankaferd Hemostat) on the Lymphoid Neoplastic Cells (B-CLL and RAJI Tumor Cell Lines)**
AKALIN İ., Okur F. V., HAZNEDAROĞLU İ. C., SAYINALP N., AKSU S., BÜYÜKAŞIK Y., GÖKER H.
UHOD-ULUSLARARASI HEMATOLOJİ-ONKOLOJİ DERGİSİ, vol.24, no.4, pp.253-259, 2014 (SCI-Expanded)
- LXXXIV. **An Immune Thrombocytopenic Purpura-Like Picture Preceding Chronic Myelomonocytic Leukemia: A Case Series and Review of the Literature**
Albayrak M., ELİAÇIK E., KORUCU B., Isik A., GÜNEŞ G., AKSU S., GÖKER H., DEMİROĞLU H., SAYINALP N., HAZNEDAROĞLU İ. C., et al.
UHOD-ULUSLARARASI HEMATOLOJİ-ONKOLOJİ DERGİSİ, vol.24, no.3, pp.213-216, 2014 (SCI-Expanded)
- LXXXV. **Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic hematopoietic stem cell transplantation for acute leukemia patients: A single center experience**
GÖKER H., Ozdemir E., UZ B., BÜYÜKAŞIK Y., Turgut M., SEREFHANOĞLU S., AKSU S., SAYINALP N., HAZNEDAROĞLU İ. C., TEKİN F., et al.
TRANSFUSION AND APHERESIS SCIENCE, vol.49, no.3, pp.590-599, 2013 (SCI-Expanded)
- LXXXVI. **Local hematopoietic renin-angiotensin system in myeloid versus lymphoid hematological neoplastic disorders**
Uz B., Tatonyan S. C., Sayitoglu M., Erbilgin Y., Ng O. H., BÜYÜKAŞIK Y., SAYINALP N., AKSU S., GÖKER H., ÖZCEBE O. İ., et al.
JOURNAL OF THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM, vol.14, no.4, pp.308-314, 2013 (SCI-Expanded)
- LXXXVII. **Co-expression of t(5;17) and t(8;21) in a Case of Acute Promyelocytic Leukemia: Review of the Literature**
Uz B., ELİAÇIK E., Isik A., AKSU S., BÜYÜKAŞIK Y., HAZNEDAROĞLU İ. C., GÖKER H., SAYINALP N., ÖZCEBE O. İ.
TURKISH JOURNAL OF HEMATOLOGY, vol.30, no.4, pp.400-404, 2013 (SCI-Expanded)
- LXXXVIII. **EUTOS CML prognostic scoring system predicts ELN-based 'event-free survival' better than Euro/Hasford and Sokal systems in CML patients receiving front-line imatinib mesylate**
Uz B., BÜYÜKAŞIK Y., Atay H., KELKİTLİ E., Turgut M., BEKTAŞ Ö., ELİAÇIK E., Isik A., AKSU S., GÖKER H., et al.
HEMATOLOGY, vol.18, no.5, pp.247-252, 2013 (SCI-Expanded)
- LXXXIX. **The Impact of Eltrombopag Administration on the Clinical Course of Severe Refractory Fatal Acquired Aplastic Anemia**
Isik A., ELİAÇIK E., HAZNEDAROĞLU İ. C., AKSU S., SAYINALP N., BÜYÜKAŞIK Y., GÖKER H., Ozcebe O.
TURKISH JOURNAL OF HEMATOLOGY, vol.30, no.3, pp.328-330, 2013 (SCI-Expanded)
- XC. **ULTRASTRUCTURAL ANALYSES OF THE NOVEL CHIMERIC HEMOSTATIC AGENT GENERATED VIA NANOTECHNOLOGY, ABS NANOHEMOSTAT, AT THE RENAL TISSUE LEVEL**
Huri E., HAZNEDAROĞLU İ. C., Hayran M., Ergun M., FIRAT A., Beyazit Y., Mammadov R., Guler M., Dadali M., GÖKER H.
HAEMATOLOGICA, vol.98, pp.439, 2013 (SCI-Expanded)
- XCI. **Long-Term Sustained Hemorrhage Due to Bone Marrow Biopsy Successfully Treated With Topical Ankaferd Hemostat in a Bleeding-Prone Patient With Secondary Amyloidosis**
Uz B., SAİN GÜVEN G., Isik A., KUYUMCU M. E., BEKTAŞ Ö., ELİAÇIK E., AKSU S., GÖKER H., BÜYÜKAŞIK Y., SAYINALP N., et al.
CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, vol.19, no.3, pp.338-340, 2013 (SCI-Expanded)
- XCII. **Prognostic importance of additional cytogenetic anomalies in chronic myeloid leukemia**
BOZKURT S., Uz B., BÜYÜKAŞIK Y., BEKTAŞ Ö., Inanc A., GÖKER H., KANSU E.
MEDICAL ONCOLOGY, vol.30, no.1, 2013 (SCI-Expanded)
- XCIII. **Hyper-CVAD Regimen in Routine Management of Adult Acute Lymphoblastic Leukemia: A Retrospective Multicenter Study**

BÜYÜKAŞIK Y., Acar K., Kelkitli E., UZ B., SEREFHANOĞLU S., Ozdemir E., Pamukcuoglu M., Atay H., Bektas O., Sucak G. T., et al.

ACTA HAEMATOLOGICA, vol.130, no.3, pp.199-205, 2013 (SCI-Expanded)

XCIV. Renin-Angiotensin System (RAS) Expressions in Myeloid Leukemic Cell Lines

UZ B., Tatonyan S. C., Sayitoglu M., Erbilgin Y., Hatirnaz Ng O., BÜYÜKAŞIK Y., AKSU S., SAYINALP N., GÖKER H., ÖZCEBE O. İ., et al.

UHOD-ULUSLARARASI HEMATOLOJİ-ONKOLOJİ DERGİSİ, vol.23, no.4, pp.264-268, 2013 (SCI-Expanded)

XCIV. Bone Marrow Iron Staining is a Reliable Test for Elimination of Iron Deficiency Anemia Rather than its Diagnosis

Koca E., Cetiner D. A., BÜYÜKAŞIK Y., ÜNER A., SAYINALP N., HAZNEDAROĞLU İ. C., GÖKER H., AKSU S., ÖZCEBE O. İ.

UHOD-ULUSLARARASI HEMATOLOJİ-ONKOLOJİ DERGİSİ, vol.23, no.4, pp.260-263, 2013 (SCI-Expanded)

XCVI. Mobilized peripheral blood stem cells compared with bone marrow from HLA-identical siblings for reduced-intensity conditioning transplantation in acute myeloid leukemia in complete remission: a retrospective analysis from the Acute Leukemia Working Party of EBMT

Nagler A., Labopin M., Shimoni A., Mufti G. J., Cornelissen J. J., Blaise D., Janssen J. J. W. M., Milpied N., Vindelov L., Petersen E., et al.

EUROPEAN JOURNAL OF HAEMATOLOGY, vol.89, no.3, pp.206-213, 2012 (SCI-Expanded)

XCVII. Effective Molecular Monitoring and the Proper Management of Pleural Effusion During the First-Line Dasatinib Administration in CML

AKSU S., BEKTAŞ Ö., UZ B., BÜYÜKAŞIK Y., SAYINALP N., ÖZCEBE O., GÖKER H., HAZNEDAROĞLU İ. C.

UHOD-ULUSLARARASI HEMATOLOJİ-ONKOLOJİ DERGİSİ, vol.22, no.1, pp.1-7, 2012 (SCI-Expanded)

XCVIII. A Placebo-Controlled, Randomized, Double-Blinded, Cross-Over Phase-I Clinical Study Indicating the Safety of Topical Ankaferd Hemostat in Healthy Volunteers

Balcik O. S., Koroglu M., Cipil H., Kaftan O., Maral S., Gurel A., GÖKER H., HAZNEDAROĞLU İ. C., Kosar A.

UHOD-ULUSLARARASI HEMATOLOJİ-ONKOLOJİ DERGİSİ, vol.22, no.4, pp.267-274, 2012 (SCI-Expanded)

XCIX. Unusual Extramedullary Recurrence and Renal Relapse Despite Complete Chimerysm after Allografting in Ph+ ALL

Serefhanoglu S., GÖKER H., BAYDAR D., ÜNER A., ARICI M., HAZNEDAROĞLU İ. C., BÜYÜKAŞIK Y., SAYINALP N., AKSU S., ÖZCEBE O. İ.

UHOD-ULUSLARARASI HEMATOLOJİ-ONKOLOJİ DERGİSİ, vol.22, no.1, pp.46-50, 2012 (SCI-Expanded)

C. Eculizumab before and after allogeneic hematopoietic stem cell transplantation in a patient with paroxysmal nocturnal hemoglobinuria

GÖKER H., UZ B., BÜYÜKAŞIK Y., AKSU S., Haznedaroglu I., SAYINALP N., Karacan Y., Tekin F., ÖZCEBE O. İ.

TURKISH JOURNAL OF HEMATOLOGY, vol.28, no.3, pp.223-227, 2011 (SCI-Expanded)

CI. Surgical and histopathological effects of topical Ankaferd (R) hemostat on major arterial vessel injury related to elevated intra-arterial blood pressure

Ulus A. T., TURAN DURAL N. N., Ozyalcin S., Aydog G., Ulus F., GÖKER H., HAZNEDAROĞLU İ. C.

TURKISH JOURNAL OF HEMATOLOGY, vol.28, no.3, pp.206-212, 2011 (SCI-Expanded)

CII. Naturally acquired hepatitis A antibodies after haematopoietic stem cell transplantation

YALÇIN S. S., Kondolot M., GÖKER H., KUŞKONMAZ B. B., Karacan Y., ÇETİN M., AKSU S., Tezcan I., Uckan D.

EPIDEMIOLOGY AND INFECTION, vol.139, no.5, pp.683-687, 2011 (SCI-Expanded)

CIII. A Comparison of Jurkat Cell-Reactive Anti-T Lymphocyte Globulin and Fetal Anti-Thymocyte Globulin Preparations in the Treatment of Aplastic Anemia

Serefhanoglu S., Buyukasik Y., Purnak T., Goker H., Sayinalp N., Haznedaroglu I. C., Ozcebe O. I.

MEDICAL PRINCIPLES AND PRACTICE, vol.20, no.4, pp.341-344, 2011 (SCI-Expanded)

CIV. Topical Ankaferd Bloodstopper in the Management of Critical Bleedings due to Hemorrhagic Diathesis

Turgut M., Tutkun F., Celebi N., MUĞLALI M., HAZNEDAROĞLU İ. C., GÖKER H.

UHOD-ULUSLARARASI HEMATOLOJİ-ONKOLOJİ DERGİSİ, vol.21, no.3, pp.160-165, 2011 (SCI-Expanded)

CV. Addition of thalidomide to oral melphalan/prednisone in patients with multiple myeloma not eligible for transplantation: results of a randomized trial from the Turkish Myeloma Study Group

BEKSAÇ M., HAZNEDAR R., Firatli-Tuglular T., Ozdogu H., Aydogdu I., Konuk N., Sucak G., Kaygusuz I., Karakus S., KAYA E., et al.

EUROPEAN JOURNAL OF HAEMATOLOGY, vol.86, no.1, pp.16-22, 2011 (SCI-Expanded)

- CVI. **Identification of clinical and simple laboratory variables predicting responsible gastrointestinal lesions in patients with iron deficiency anemia**
Serefhanoglu S., BÜYÜKAŞIK Y., Emmungil H., SAYINALP N., HAZNEDAROĞLU İ. C., GÖKER H., AKSU S., ÖZCEBE O. İ.
INTERNATIONAL JOURNAL OF MEDICAL SCIENCES, vol.8, no.1, pp.30-38, 2011 (SCI-Expanded)
- CVII. **Clinical features and outcomes of 49 Turkish patients with acute promyelocytic leukemia who received ATRA and anthracyclines (PETHEMA protocol) therapy**
SEREFHANOGLU S., BÜYÜKAŞIK Y., GÖKER H., SAYINALP N., HAZNEDAROĞLU İ. C., AKSU S., ÖZCEBE O. İ., Turgut M., Aslan R., Ozdemir E.
LEUKEMIA RESEARCH, vol.34, no.12, 2010 (SCI-Expanded)
- CVIII. **Evaluation of Hemostatic Effects of Ankaferd as an Alternative Medicine**
Beyazit Y., Kurt M., Kekilli M., GÖKER H., HAZNEDAROĞLU İ. C.
ALTERNATIVE MEDICINE REVIEW, vol.15, no.4, pp.329-336, 2010 (SCI-Expanded)
- CIX. **Determination of burnout levels of nurses working in stem cell transplantation units in Turkey**
AKKUŞ Y., Karacan Y., GÖKER H., AKSU S.
NURSING & HEALTH SCIENCES, vol.12, no.4, pp.444-449, 2010 (SCI-Expanded)
- CX. **Oral Systemic Administration of Ankaferd Blood Stopper Has No Short-Term Toxicity in an In Vivo Rabbit Experimental Model**
Bilgili H., Captug O., Kosar A., Kurt M., Kekilli M., Shorbagi A., Kurt O. K., Ozdemir O., GÖKER H., HAZNEDAROĞLU İ. C.
CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, vol.16, no.5, pp.533-536, 2010 (SCI-Expanded)
- CXI. **Serological response to influenza vaccine after hematopoietic stem cell transplantation**
YALÇIN Ş., Kondolot M., Albayrak N., Altas A. B., Karacan Y., Kuskonmaz B. B., AKSU S., Cetin M., GÖKER H., YURDAKÖK K., et al.
ANNALS OF HEMATOLOGY, vol.89, no.9, pp.913-918, 2010 (SCI-Expanded)
- CXII. **Ultrastructural and Morphological Analyses of the In Vitro and In Vivo Hemostatic Effects of Ankaferd Blood Stopper**
HAZNEDAROĞLU B. Z., HAZNEDAROĞLU İ. C., WALKER S. L., Bilgili H., GÖKER H., Kosar A., AKTAŞ A., Captug O., Kurt M., OZDEMİR O., et al.
CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, vol.16, no.4, pp.446-453, 2010 (SCI-Expanded)
- CXIII. **Prognostic Factors Affecting the Clinical Course of non-Hodgkin's Lymphomas**
Beyazit Y., Kekilli M., Purnak T., GÖKER H., AKSU S., HAZNEDAROĞLU İ. C., ÖZCEBE O. İ.
UHOD-ULUSLARARASI HEMATOLOJİ-ONKOLOJİ DERGİSİ, vol.20, no.2, pp.96-102, 2010 (SCI-Expanded)
- CXIV. **Antimicrobial activity of Ankaferd Blood StopperA (R) against nosocomial bacterial pathogens**
SARIBAŞ Z., ŞENER B., HAZNEDAROĞLU İ. C., Hascelik G., Kirazli S., GÖKER H.
CENTRAL EUROPEAN JOURNAL OF MEDICINE, vol.5, no.2, pp.198-202, 2010 (SCI-Expanded)
- CXV. **Safety and Efficacy of Ankaferd Blood Stopper in Dental Surgery**
ERCETIN S., HAZNEDAROĞLU İ. C., Kurt M., ONAL I. K., AKTAŞ A., KURT O. K., GÖKER H., OZDEMİR O., KIRAZLI S., FIRAT H. C.
UHOD-ULUSLARARASI HEMATOLOJİ-ONKOLOJİ DERGİSİ, vol.20, no.1, pp.1-5, 2010 (SCI-Expanded)
- CXVI. **Dasatinib-Induced Tumor Lysis Syndrome and Following Hematologic Remission in Fibrotic Blastic Crisis of CML**
BEKTAŞ Ö., HAZNEDAROĞLU İ. C., BÜYÜKAŞIK Y., SAYINALP N., AKSU S., GÖKER H., ÖZCEBE O. İ.
UHOD-ULUSLARARASI HEMATOLOJİ-ONKOLOJİ DERGİSİ, vol.20, no.2, pp.13-16, 2010 (SCI-Expanded)
- CXVII. **Concomitant renal cell carcinoma and lymphoid malignancies: a case series of five patients and review of the literature**
Serefhanoglu S., BÜYÜKAŞIK Y., GÖKER H., Akin S. C., Akin S., SAYINALP N., HAZNEDAROĞLU İ. C., ÖZCEBE O. İ.
MEDICAL ONCOLOGY, vol.27, no.1, pp.55-58, 2010 (SCI-Expanded)
- CXVIII. **Spinal Myeloid Sarcoma in Two Non-Leukemic Patients**
Serefhanoglu S., GÖKER H., AKSU S., BÜYÜKAŞIK Y., SAYINALP N., HAZNEDAROĞLU İ. C., ÖZCEBE O. İ.

INTERNAL MEDICINE, vol.49, no.22, pp.2493-2497, 2010 (SCI-Expanded)

- CXIX. **The Gray-Zone Concept, Suboptimal Response to Imatinib, Shall be Removed from the ELN-CML Recommendations**
HAZNEDAROĞLU İ. C., Koca E., AKSU S., GÖKER H., SAYINALP N., BÜYÜKAŞIK Y., ÖZCEBE O. İ.
UHOD-ULUSLARARASI HEMATOLOJİ-ONKOLOJİ DERGİSİ, vol.20, no.2, pp.25-26, 2010 (SCI-Expanded)
- CXX. **Changes in vascular endothelial growth factor, angiopoietins, and Tie-2 levels with G-CSF stimulation in healthy donors**
Serefhanoglu S., GÖKER H., BÜYÜKAŞIK Y., Turgut M., SAYINALP N., HAZNEDAROĞLU İ. C., AKSU S., Akman U., ÖZCEBE O. İ.
ANNALS OF HEMATOLOGY, vol.88, no.7, pp.667-671, 2009 (SCI-Expanded)
- CXXI. **In Vivo Hemostatic Effect of the Medicinal Plant Extract Ankaferd Blood Stopper in Rats Pretreated With Warfarin**
Cipil H. S., Kosar A., Kaya A., Uz B., HAZNEDAROĞLU İ. C., GÖKER H., Ozdemir O., Koroglu M., Kirazli S., Firat H. C.
CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, vol.15, no.3, pp.270-276, 2009 (SCI-Expanded)
- CXXII. **Transformation of Adult Myelodysplastic Syndrome-Refractory Anemia to Acute T-Cell Lymphoblastic Leukemia**
Serefhanoglu S., GÖKER H., BÜYÜKAŞIK Y., SAYINALP N., ÖZCEBE O. İ.
JOURNAL OF THE NATIONAL MEDICAL ASSOCIATION, vol.101, no.4, pp.370-372, 2009 (SCI-Expanded)
- CXXIII. **The efficacy of Ankaferd Blood Stopper in antithrombotic drug-induced primary and secondary hemostatic abnormalities of a rat-bleeding model**
Kosar A., Cipil H. S., Kaya A., Uz B., HAZNEDAROĞLU İ. C., GÖKER H., Ozdemir O., Ercetin S., Kirazli S., Firat H. C.
BLOOD COAGULATION & FIBRINOLYSIS, vol.20, no.3, pp.185-190, 2009 (SCI-Expanded)
- CXXIV. **In Vitro Anti-Bacterial Activities of Ankaferd Medicinal Plant Extract**
Akkoc N., AKÇELİK M., HAZNEDAROĞLU İ. C., GÖKER H., Turgut M., AKSU S., Kirazli S., Firat H. C.
TURKIYE KLİNİKLERİ TIP BİLİMLERİ DERGİSİ, vol.29, no.2, pp.410-415, 2009 (SCI-Expanded)
- CXXV. **The Effect of the Chernobyl Disaster on the Occurrence of Adult Acute Leukemias in Turkey**
Ozatli D., GÖKER H., Buyukasik Y., Sayinalp N., HAZNEDAROĞLU İ. C., ÖZCEBE O. İ.
TURKIYE KLİNİKLERİ TIP BİLİMLERİ DERGİSİ, vol.29, no.2, pp.388-394, 2009 (SCI-Expanded)
- CXXVI. **Biphenotypic Acute Leukemia Treated With Acute Myeloid Leukemia Regimens: A Case Series**
Serefhanoglu S., BÜYÜKAŞIK Y., GÖKER H., SAYINALP N., ÖZCEBE O. İ.
JOURNAL OF THE NATIONAL MEDICAL ASSOCIATION, vol.101, no.3, pp.270-272, 2009 (SCI-Expanded)
- CXXVII. **Multiple Bulky Cutaneous Plasmacytomas with CNS Relapse without Bone Marrow Involvement during the Course of a Lambda Light Chain Myeloma**
Serefhanoglu S., HAZNEDAROĞLU İ. C., GÖKER H., BÜYÜKAŞIK Y., ÖZCEBE O. İ.
ONKOLOGIE, vol.32, no.11, pp.662-664, 2009 (SCI-Expanded)
- CXXVIII. **Hemostatic Efficacy of Ankaferd Blood Stopper (R) in a Swine Bleeding Model**
Bilgili H., Kosar A., Kurt M., Onal I. K., GÖKER H., Captug O., Shorbagi A., Turgut M., Kekilli M., Kurt O. K., et al.
MEDICAL PRINCIPLES AND PRACTICE, vol.18, no.3, pp.165-169, 2009 (SCI-Expanded)
- CXXIX. **Haemostatic actions of the folkloric medicinal plant extract Ankaferd Blood Stopper Response**
HAZNEDAROĞLU İ. C., GÖKER H.
JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, vol.36, no.6, pp.1448-1449, 2008 (SCI-Expanded)
- CXXX. **Effect of platelet count on secretion capacity: formulization and use of the formulae for evaluation of platelet secretion in thrombocytopenic patients**
BÜYÜKAŞIK Y., GÖKER H., Buyukasik N. S., SAYINALP N., HAZNEDAROĞLU İ. C., Ozcebea O. I.
BLOOD COAGULATION & FIBRINOLYSIS, vol.19, no.7, pp.633-637, 2008 (SCI-Expanded)
- CXXXI. **Extramedullary plasmacytomas of the thyroid and pericardium as initial presentation of multiple myeloma**
Serefhanoglu S., SAYINALP N., HAZNEDAROĞLU İ. C., GÖKER H., Cetiner D., AKSU S., BÜYÜKAŞIK Y., ÖZCEBE O. İ.
ANNALS OF HEMATOLOGY, vol.87, no.10, pp.853-854, 2008 (SCI-Expanded)
- CXXXII. **Evidence for higher red blood cell mass in persons with unconjugated Hyperbilirubinemia and Gilbert's syndrome**

- BÜYÜKAŞIK Y., Akman U., Buyukasik N. S., GÖKER H., Kilicarslan A., Shorbagi A. I., Hascelik G., HAZNEDAROĞLU İ. C.
AMERICAN JOURNAL OF THE MEDICAL SCIENCES, vol.335, no.2, pp.115-119, 2008 (SCI-Expanded)
- CXXXIII. **Soluble platelet glycoprotein V in distinct disease states of pathological thrombopoiesis**
Acar K., AKSU S., Beyazit Y., HAZNEDAROĞLU İ. C., Koca E., Cetiner D., Sayinalp N., BÜYÜKAŞIK Y., GÖKER H., Kirazli S., et al.
JOURNAL OF THE NATIONAL MEDICAL ASSOCIATION, vol.100, no.1, pp.86-90, 2008 (SCI-Expanded)
- CXXXIV. **Angiotensin-converting enzyme expression of the lymphoma-associated macrophages in the lymph nodes of Hodgkin's disease**
Koca E., Haznedaroglu I. C., ÜNER A., Sayinalp N., Saglam A. E., Goker H., Ozcebe O. I.
JOURNAL OF THE NATIONAL MEDICAL ASSOCIATION, vol.99, no.11, pp.1243-1246, 2007 (SCI-Expanded)
- CXXXV. **Chemotherapy and imatinib-induced molecular remission in lymphoid blast crisis after 20 years of "untreated" chronic myeloid leukemia**
Koca E., Sevimli F., Cetiner D., Haznedaroglu I. C., Sayinalp N., Buyukasik Y., Goker H., Ozcebe O.
AMERICAN JOURNAL OF HEMATOLOGY, vol.82, no.4, pp.333, 2007 (SCI-Expanded)
- CXXXVI. **Plasma osteopontin levels are elevated in non-ST-segment elevation acute coronary syndromes**
Coskun S., Atalar E., Ozturk E., Yavuz B., Ozer N., Goker H., Ovunc K., Aksoyek S., Kes S., Sivri B., et al.
JOURNAL OF THE NATIONAL MEDICAL ASSOCIATION, vol.98, no.11, pp.1746-1750, 2006 (SCI-Expanded)
- CXXXVII. **Over-expression of angiotensin-converting enzyme (CD 143) on leukemic blasts as a clue for the activated local bone marrow RAS in AML**
Aksu S., Beyazit Y., Haznedaroglu I. C., Canpinar H., Kekilli M., ÜNER A., Sayinalp N., Bueyuekasik Y., Goker H., Ozcebe O. I.
LEUKEMIA & LYMPHOMA, vol.47, no.5, pp.891-896, 2006 (SCI-Expanded)
- CXXXVIII. **Couda equina syndrome as a rare manifestation of leukemia relapse during postallograft period**
Önal I. K., Shorbagi A., GÖKER H., Büyükaşık Y., ÖZÇAKAR L., Tufan A., AKSU S., Haznedaroglu İ. C.
Journal of the National Medical Association, vol.98, no.5, pp.808-810, 2006 (SCI-Expanded)
- CXXXIX. **Spontaneous splenic rupture in a healthy allogeneic donor of peripheral-blood stem cell following the administration of granulocyte colony-stimulating factor (g-csf). A case report and review of the literature**
Nuamah N. M., GÖKER H., Kilic Y. A., Dagmoura H., ÇAKMAK A.
HAEMATOLOGICA, vol.91, pp.26-28, 2006 (SCI-Expanded)
- CXL. **Synthesis and crystal structure elucidation of 1-(4-fluorobenzyl)-2-(4-cyanophenyl)-1H-benzimidazole-5-carbonitrile**
Ozbey S., KAYNAK F. B., GOKER H., KUS C.
JOURNAL OF CHEMICAL CRYSTALLOGRAPHY, vol.34, no.12, pp.851-858, 2004 (SCI-Expanded)
- CXLI. **2-(2,4-Dichlorophenyl)-5-fluoro-6-morpholin-4-yl-1H-benzimidazole monohydrate**
Ozbey S., KAYNAK F. B., KUS C., GOKER H.
ACTA CRYSTALLOGRAPHICA SECTION E-STRUCTURE REPORTS ONLINE, vol.58, 2002 (SCI-Expanded)
- CXLII. **Crystal structure of 1-cyclopropyl-2-ethyl-5-fluoro-6-(4-methylpiperazin-1-yl)-1H-benzimidazole**
Ozbey S., KUS C., GOKER H.
ANALYTICAL SCIENCES, vol.17, no.8, pp.1019-1020, 2001 (SCI-Expanded)
- CXLIII. **Synthesis and antihistaminic H-1 activity of 1,2,5(6)-trisubstituted benzimidazoles**
GOKER H., AYHAN-KILCIGIL G., TUNCBILEK M. G., KUS C., ERTAN R., KENDI E., Ozbey S., FORT M., GARCIA C., FARRE A.
HETEROCYCLES, vol.51, no.11, pp.2561-2573, 1999 (SCI-Expanded)
- CXLIV. **2,5-dichloro-1-(p-chlorobenzyl)-1H-benzimidazole**
KENDI E., Ozbey S., GOKER H.
ACTA CRYSTALLOGRAPHICA SECTION C-CRYSTAL STRUCTURE COMMUNICATIONS, vol.55, pp.243-245, 1999 (SCI-Expanded)
- CXLV. **1-benzyl-2-(2,6-dichloroanilinomethyl)-1H-benzimidazole**
KENDI E., Ozbey S., TUNCBILEK M. G., GOKER H.
ACTA CRYSTALLOGRAPHICA SECTION C-CRYSTAL STRUCTURE COMMUNICATIONS, vol.54, pp.854-856, 1998 (SCI-

Expanded)

- CXLVI. **The structure of 1-(p-fluorophenylmethyl)-2-(4-methyl-1-piperazinyl)-1H-benzimidazole hydrogen fumarate**
Ozbey S., KENDI E., GOKER H., TUNCBILEK M. G.
JOURNAL OF CHEMICAL CRYSTALLOGRAPHY, vol.28, no.6, pp.461-464, 1998 (SCI-Expanded)
- CXLVII. **2-(2-ethoxycarbonyl-1,4-benzodioxan-7-yl)-4H-1-benzopyran-4-one**
Ozbey S., KENDI E., GOKER H., ERTAN R.
ACTA CRYSTALLOGRAPHICA SECTION C-CRYSTAL STRUCTURE COMMUNICATIONS, vol.53, pp.1981-1983, 1997 (SCI-Expanded)
- CXLVIII. **Synthesis of some new benzimidazole-5(6)-carboxylic acids**
GOKER H., OLGUN S., ERTAN R., AKGUN H., Ozbey S., KENDI E., TOPCU G.
JOURNAL OF HETEROCYCLIC CHEMISTRY, vol.32, no.6, pp.1767-1773, 1995 (SCI-Expanded)

Articles Published in Other Journals

- I. **Exploring the distribution and prognostic effect of the ABO blood types of COVID-19 patients during delta and omicron waves: A case control study**
GÖKER H., ÇINAR O. E., ISMAYILOV R., Özdemir E., MALKAN Ü. Y., ALADAĞ E., BÜYÜKAŞIK Y., SAYINALP N., HAZNEDAROĞLU İ., ÖZCEBE O., et al.
Acta Medica, vol.54, no.2, pp.97-102, 2023 (Peer-Reviewed Journal)
- II. **Comparison of bortezomib-cyclophosphamide-dexamethasone versus bortezomib-dexamethasone based regimens in newly diagnosed multiple myeloma patients**
Çiftçiler R., GÖKER H., BÜYÜKAŞIK Y., SAYINALP N., HAZNEDAROĞLU İ. C., AKSU S., Özcebe O., DEMİROĞLU H.
HEMATOLOGY REPORTS, vol.12, no.1, 2020 (ESCI)
- III. **DETERMINANTS OF CARDIORESPIRATORY FITNESS LEVEL IN HEMATOPOIETIC STEM CELL TRANSPLANTATION CANDIDATES**
YILDIZ KABAK V., GÖKER H., ATASAVUN UYSAL S., DEMİROĞLU H., ALADAĞ KARAKULAK E., OKAY M., DÜGER T.
TURKISH JOURNAL OF PHYSIOTHERAPY REHABILITATION-TURK FIZYOTERAPI VE REHABILITASYON DERGISI, vol.30, no.2, pp.81-88, 2019 (ESCI)
- IV. **Evaluation of Secondary Malignancies in Chronic Lymphocytic Leukemia**
DEMİROĞLU H., SAYINALP N., GÖKER H., BÜYÜKAŞIK Y., ÖZCEBE O. İ., HAZNEDAROĞLU İ. C., OKAY M., ÇİFTÇİLER R., heziyev t
Journal of Global Oncology, pp.205, 2018 (ESCI)
- V. **Immunosuppression-associated posterior reversible encephalopathy syndrome in an acute leukemia case**
Malkan U. Y., GÜNEŞ G., DEMİROĞLU H., GÖKER H.
HEMATOLOGY REPORTS, vol.10, no.4, pp.96-97, 2018 (ESCI)
- VI. **Late Onset and Protracted Course of Steroid Refractory Chronic Graft-versus-Host Disease**
GÜNEŞ G., DEMİROĞLU H., GÖKER H., Malkan Ü. Y., ELİAÇIK E., Yayar O., BÜYÜKAŞIK Y.
CASE REPORTS IN HEMATOLOGY, 2015 (ESCI)
- VII. **THE FACTORS INFLUENCING OVERALL SURVIVAL IN NEWLY DIAGNOSED ADULT ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS**
Serefhanoglu S., BÜYÜKAŞIK Y., AKSU S., GÖKER H., SAYINALP N., Cetgner D., HAZNEDAROĞLU İ. C., ÖZCEBE O. İ.
JOURNAL OF ISTANBUL FACULTY OF MEDICINE-ISTANBUL TIP FAKULTESİ DERGISI, vol.74, no.1, pp.7-12, 2011 (ESCI)
- VIII. **DISEASE CHARACTERISTICS AND FACTORS INFLUENCING TREATMENT RESPONSE IN NEWLY DIAGNOSED ACUTE MYELOBLASTIC LEUKEMIA PATIENTS: A SINGLE CENTER EXPERIENCE**
Serefhanoglu S., BÜYÜKAŞIK Y., AKSU S., GÖKER H., SAYINALP N., Cetiner D., HAZNEDAROĞLU İ. C., ÖZCEBE O. İ.
JOURNAL OF ISTANBUL FACULTY OF MEDICINE-ISTANBUL TIP FAKULTESİ DERGISI, vol.73, no.3, pp.74-79, 2010 (ESCI)

Books & Book Chapters

- I. **Klinik Pratikte Hematoloji**
HAZNEDAROĞLU İ. C., TURGUT M., GÖKER H., BÜYÜKAŞIK Y.
nobel tıp kitabevleri, Ankara, 2019

Refereed Congress / Symposium Publications in Proceedings

- I. **Proceedings of the World Congress of Gastroenterology**
BALABAN H. Y., ASLAN A. T., AKDOĞAN KİTTANA F. N., ALP A., DAĞ O., AYAR Ş. N., MUSTAYEV F., Vahabov C., YILDIRIM T., GÖKER H., et al.
World Congress of Gastroenterology, İstanbul, Turkey, 21 September 2019, vol.30, pp.729
- II. **Incidence and risk factors for hepatic sinusoidal obstruction syndrome after allogeneic transplantation: Retrospective multicenter study of Turkish hematology research and education group (THREG), updated data**
SOYER N., Gunduz M., Tekgunduz E., Deveci B., Ozdogu H., ŞAHİN H. H., ERMİŞ TURAK E., OKAY M., KUKU İ., Hindilerden I. Y., et al.
45th Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation (EBMT), Frankfurt, Germany, 24 - 27 March 2019, vol.54, pp.254-255
- III. **AZACYTIDINE BEFORE ALLOGENEIC STEM CELL TRANSPLANTATION IS INFERIOR TO HD/ARA-C WITHRESPECT TO RELAPSE FOLLOWING TRANSPLANTATION**
DEMİROĞLU H., OKAY M., ÇİFTÇİLER R., ALADAĞ KARAKULAK E., GÜL Ö., BÜYÜKAŞIK Y., GÖKER H.
24th EHA Congress, 13 - 16 June 2019, vol.3, pp.941-942
- IV. **THE EVALUATION OF THE CLINICOPATHOLOGIC CHARACTERISTICS OF T-CELL NON-HODGKIN'S LYMPHOMA: THE SINGLE CENTER EXPERIENCE**
SAYINALP N., ALADAĞ KARAKULAK E., OKAY M., ÇİFTÇİLER R., AKSU S., DEMİROĞLU H., BÜYÜKAŞIK Y., GÖKER H., HAZNEDAROĞLU İ. C., ÖZCEBE O. İ.
15th International Conference on Malignant Lymphoma, Switzerland, 18 - 22 June 2019, vol.37, pp.366
- V. **HEMATOLOJİK MALİGNİTELERDE DONÖR LENFOSİT İNFÜZYONU ÖNCESİ VERİLEN KEMOTERAPİ SIKLUS SAYISININ SAĞKALIMA ETKİSİ**
ALADAĞ KARAKULAK E., OKAY M., ÇİFTÇİLER R., BÜYÜKAŞIK Y., GÖKER H., DEMİROĞLU H.
4. ULUSAL KAN VE KEMİK İLİĞİ NAKLİ KONGRESİ, Cyprus (Kktc), 4 - 06 April 2019
- VI. **ASEMPTOMATİK D-DİMER YÜKSEKLİĞİ İMMÜNMONULATUAR KULLANAN MULTİPLE MYELOMADA TROMBOZU TAHMİN EDER Mİ: GERÇEK YAŞAM VERİSİ**
AYDIN M. S., ALADAĞ KARAKULAK E., ÇİFTÇİLER R., YAZGAN S. Ç., DEMİROĞLU H., ÖZCEBE O. İ., HAZNEDAROĞLU İ. C., AKSU S., GÖKER H.
4. ULUSAL KAN VE KEMİK İLİĞİ NAKLİ KONGRESİ, Cyprus (Kktc), 4 - 06 April 2019
- VII. **Hematopoietic Stem Cell Transplantation for HIV-positive Patients with Hematologic Malignancies: Three Patients Experience from Turkey**
Çiftçiler R., GÖKER H., İNKAYA A. Ç., ÜNAL S., DEMİROĞLU H.
International Forum on Infectious Diseases, İstanbul, Turkey, 21 - 24 March 2019, pp.11-14
- VIII. **MULTİPLE MYELOM HASTALARINDA İNDUKSİYON TEDAVİ SÜRESİNİN SAĞKALIMA ETKİSİ**
ALADAĞ KARAKULAK E., OKAY M., ÇİFTÇİLER R., DEMİROĞLU H., AKSU S., BÜYÜKAŞIK Y., HAZNEDAROĞLU İ. C., SAYINALP N., ÖZCEBE O. İ., GÖKER H.
3. HEMATOLOJİK İMMUNOLOJİ KONGRESİ, Turkey, 8 - 09 March 2019
- IX. **Hepatitis E Virus Epidemiology and Genotype Analysis Among Special Risk Groups in Turkey, 16. Ulusal Hepato Gastroenteroloji Kongresi, 17-23 Ekim 2019-Girne, KKTC.**
ASLAN A. T., BALABAN H. Y., AYAR Ş. N., AKDOĞAN KİTTANA F. N., ALP A., Vahabov C., PÜRNAK T., YILDIRIM T., GÖKER H., ERDEM Y., et al.
16. Ulusal Hepato Gastroenteroloji Kongresi, Girne, Cyprus (Kktc), 31 October 2018

- X. **Long-Term Results of Non-Fludarabine Versus Fludarabine-Based Conditioning Regimens in Severe Aplastic Anemia Patients**
ALADAĞ KARAKULAK E., DEMİROĞLU H., Ciftçiler R., BÜYÜKAŞIK Y., SAYINALP N., AKSU S., HAZNEDAROĞLU İ. C., Ozcebe O., Chao N. J., GÖKER H.
60th Annual Meeting of the American-Society-of-Hematology (ASH), California, United States Of America, 1 - 04 December 2018, vol.132
- XI. **Analysis of Elderly Patients with Chronic Myeloid Leukemia**
KELKİTLİ E., GÖKER H., Turgut M., ATAY M. H.
60th Annual Meeting of the American-Society-of-Hematology (ASH), California, United States Of America, 1 - 04 December 2018, vol.132
- XII. **PHILADELPHIA KROMOZOMU POZİTİF AKUT MYELOİDLÖSEMİLİ OLGU**
ÇİFTÇİLER R., ALADAĞ KARAKULAK E., OKAY M., GÖKER H., DEMİROĞLU H., BÜYÜKAŞIK Y.
44. ULUSAL HEMATOLOJİ KONGRESİ, Antalya, Turkey, 31 October - 03 November 2018, pp.340
- XIII. **DASATİNİB KULLANIRKEN PLEVRAL EFFÜZYONU GELİŞİP, KÜÇÜK HÜCRELİ AKCİĞER KANSERİ TANISI ALAN BİR OLGU**
ÇİFTÇİLER R., ALADAĞ KARAKULAK E., SAYINALP N., HAZNEDAROĞLU İ. C., ÖZCEBE O. İ., AKSU S., GÖKER H., BÜYÜKAŞIK Y., DEMİROĞLU H.
44. ULUSAL HEMATOLOJİ KONGRESİ, Antalya, Turkey, 31 October - 03 November 2018, pp.364-365
- XIV. **AĞIR APLASTİK ANEMİ HASTALARINDA HEMATOPOETİK KÖK HÜCRE NAKLİNDE KULLANILAN HAZIRLIK REJİMLERİNİN KARŞILAŞTIRILMASI**
ALADAĞ KARAKULAK E., DEMİROĞLU H., ÇİFTÇİLER R., BÜYÜKAŞIK Y., SAYINALP N., AKSU S., HAZNEDAROĞLU İ. C., ÖZCEBE O. İ., GÖKER H.
44.ULUSAL HEMATOLOJİ KONGRESİ, Antalya, Turkey, 31 October - 03 November 2018, pp.261
- XV. **PHILADELPHIA KROMOZOMU POZİTİF AKUT MYELOİD LÖSEMİLİ OLGU**
DEMİROĞLU H., GÖKER H., BÜYÜKAŞIK Y., ÇİFTÇİLER R., ALADAĞ KARAKULAK E., OKAY M.
TÜRK HEMATOLOJİ DERNEĞİ, Turkey, 31 October - 03 November 2018
- XVI. **LENALIDOMİD İLE MYELOMDA OTOLOG NAKİL SONRASI İLK NÜKSDE TALİDOMİD VE BORTEZOMİBE KİYASLA DAHA İYİ İLERLEMESİZ SAĞKALIM**
DEMİROĞLU H., AKSU S., SAYINALP N., GÖKER H., BÜYÜKAŞIK Y., ÖZCEBE O. İ., HAZNEDAROĞLU İ. C., GÜNEŞ G., Malkan Ü. Y.
TÜRK HEMATOLOJİ DERNEĞİ, Turkey, 31 October - 03 November 2018
- XVII. **MRG'DE TESADÜFEN SAPTANAN KEMİK İLİĞİNİN DİFFÜZ SİNYAL DEĞİŞİKLİKLERİ LENFOHEMATOPOETİK HASTALIKLARI ÖNGÖREBİLİR Mİ?**
ÇİFTÇİLER R., ALADAĞ KARAKULAK E., AKSU S., SAYINALP N., DEMİROĞLU H., GÖKER H., ÖZCEBE O. İ., HAZNEDAROĞLU İ. C., BÜYÜKAŞIK Y.
44. ULUSAL HEMATOLOJİ KONGRESİ, Antalya, Turkey, 31 October - 03 November 2018, pp.266
- XVIII. **T HÜCRELİ LENFOMA HASTALARININ KLİNİK ÖZELLİKLERİNİN DEĞERLENDİRİLMESİ: TANIDAN PROGNOZA TEK MERKEZ DENEYİMİ**
DEMİROĞLU H., SAYINALP N., GÖKER H., BÜYÜKAŞIK Y., ÖZCEBE O. İ., HAZNEDAROĞLU İ. C., OKAY M., ALADAĞ KARAKULAK E., ÇİFTÇİLER R.
TÜRK HEMATOLOJİ DERNEĞİ, Turkey, 31 October - 03 November 2018
- XIX. **BRENTIXUMAB VEDOTIN IN CD30 LYMPHOMAS: SINGLE CENTER EXPERIENCE**
DEMİROĞLU H., SAYINALP N., BÜYÜKAŞIK Y., ÖZCEBE O. İ., HAZNEDAROĞLU İ. C., GÖKER H., ÇİFTÇİLER R., OKAY M.
IX. INTERNATIONAL EHO, 17 - 20 October 2018, vol.73
- XX. **Extramedullary relapse of the AML following allo-HSCT: a case repor**
ÇİFTÇİLER R., ALADAĞ KARAKULAK E., OKAY M., GÖKER H.
IX. International Eurasian Hematology-Oncology Congress, Turkey, 17 - 20 October 2018, vol.71, pp.43
- XXI. **Mitoxantrone-melphalan conditioning regimen for autologous stem cell transplantation in relapsed/refractory lymphoma**
OKAY M., BÜYÜKAŞIK Y., DEMİROĞLU H., MALKAN Ü. Y., CİFTÇİLER R., Aladag E., AKSU S., HAZNEDAROĞLU İ. C., SAYINALP N., ÖZCEBE O. İ., et al.

- XXII. **AKUT MYELOİD LÖSEMİLİ BİR OLGULDA SİTOZİN ARABİNOZİD İLİŞKİLİ PULMONER TOKSİSİTE**
ÇİFTÇİLER R., ALADAĞ KARAKULAK E., HAZNEDAROĞLU İ. C., AKSU S., DEMİROĞLU H., GÖKER H., ÖZCEBE O. İ., BÜYÜKAŞIK Y., SAYINALP N.
4.İLAÇ VE TEDAVİ KONGRESİ, Cyprus (Kkct), 19 - 23 September 2018, pp.254
- XXIII. **COMPARISON OF MYELOABLATIVE AND REDUCED-INTENSITY CONDITIONING REGIMENS FOR ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH ACUTE MYELOID LEUKEMIA**
ÇİFTÇİLER R., OKAY M., ALADAĞ KARAKULAK E., BÜYÜKAŞIK Y., GÖKER H., DEMİROĞLU H.
EUROPEAN HEMATOLOGY ASSOCIATION, 14 - 17 June 2018
- XXIV. **EFFECT OF THE INDUCTION THERAPY ON SURVIVAL IN MULTIPLE MYELOMA PATIENTS**
ALADAĞ KARAKULAK E., ÇİFTÇİLER R., DEMİROĞLU H., AKSU S., BÜYÜKAŞIK Y., HAZNEDAROĞLU İ. C., SAYINALP N., ÖZCEBE O. İ., GÖKER H.
The International Congress of BMT 2018, Busan, South Korea, 30 August - 01 September 2018
- XXV. **DOES ASYMPTOMATIC D-DIMER ELEVATION PREDICT THROMBOSIS IN PATIENTS ON IMMUNOMODULATORY DRUGS IN MULTIPLE MYELOMA: REAL-LIFE DATA**
AYDIN M. S., YAZGAN S. Ç., ALADAĞ KARAKULAK E., ÇİFTÇİLER R., KELKİTLİ E., TURGUT M., GÖKER H., DEMİROĞLU H., ÖZCEBE O. İ., HAZNEDAROĞLU İ. C., et al.
23rd Congress of EHA, Stockholm, Sweden, 14 - 17 June 2018
- XXVI. **POST-TRANSPLANT EBSTEIN-BARR VIRAL LOAD MONITORING EXPERIENCE IN A HEMATOPOIETIC STEM CELL TRANSPLANTATION CENTER**
AYDIN M. S., İNKAYA A. Ç., ALADAĞ KARAKULAK E., ÇİFTÇİLER R., TURGUT M., GÖKER H., KELKİTLİ E., DEMİROĞLU H., BÜYÜKAŞIK Y., SAYINALP N.
23rd Congress of EHA, Stockholm, Sweden, 14 - 17 June 2018
- XXVII. **Posttransplant Ebstein-Barr viral load monitoring experience in a hematopoietic stem cell transplantation center**
AYDIN M. S., İnkaya Çağkan a., ALADAĞ KARAKULAK E., çiftçiler R., TURGUT M., GÖKER H., KELKİTLİ E., DEMİROĞLU H., BÜYÜKAŞIK Y., SAYINALP N.
European Hematology Association, 14 - 17 June 2018
- XXVIII. **The Novel Translocation Of T(121) In Multiple Myeloma With Complex Karyotype**
OKAY M., ÇİFTÇİLER R., ALADAĞ KARAKULAK E., GÖKER H.
23rd Congress of EHA, Stockholm, Sweden, 14 - 17 June 2018
- XXIX. **Does Asymptomatic D-Dimer Elevation Predict Thrombosis in Patient on Immunomodulatory Drugs in Multiple Myeloma: Real-Life Data**
AYDIN M. S., YAZGAN S. C., ALADAĞ KARAKULAK E., Çiftçiler R., KELKİTLİ E., TURGUT M., GÖKER H., DEMİROĞLU H., ÖZCEBE O. İ., HAZNEDAROĞLU İ. C., et al.
European Hematology Association, 14 - 17 June 2018
- XXX. **RISK FACTORS FOR EARLY MORTALITY IN MULTIPLE MYELOMA WITH DIFFERENT SURVIVAL TIME CUT-OFF POINTS: REAL-LIFE DATA**
AYDIN M. S., ALADAĞ KARAKULAK E., ÇİFTÇİLER R., DEMİROĞLU H., GÖKER H., TURGUT M., KELKİTLİ E., SAYINALP N., BÜYÜKAŞIK Y., TEKİN F.
23rd Congress of EHA, Stockholm, Sweden, 14 - 17 June 2018
- XXXI. **ANJİMMUNOBLASTİK T HÜCRELİ LENFOMA, ÇOK YÜZLÜ LENFOMA**
OKAY M., ÇİFTÇİLER R., ALADAĞ KARAKULAK E., HEZİYEV T., GÖKER H., BÜYÜKAŞIK Y.
2. HEMATOLOJİK İMMUNOLOJİ KONGRESİ, Cyprus (Kkct), 4 - 06 May 2018
- XXXII. **PLAZMA HÜCRELİ LÖSEMİ ŞEKLİNDE PREZENTE OLAN WALDENSTROM MAKROGLOBULİNEMİSİ**
ÇİFTÇİLER R., OKAY M., ALADAĞ KARAKULAK E., HEZİYEV T., AKSU S., SAYINALP N., HAZNEDAROĞLU İ. C., DEMİROĞLU H., BÜYÜKAŞIK Y., GÖKER H., et al.
2. HEMATOLOJİK İMMUNOLOJİ KONGRESİ, Cyprus (Kkct), 4 - 06 May 2018
- XXXIII. **Common medical problems in adult patients with Hemophilia A: A single center experience**
AYDIN M. S., OKAY M., ÇİFTÇİLER R., ALADAĞ KARAKULAK E., DEMİROĞLU H., GÖKER H., BÜYÜKAŞIK Y., ÖZCEBE O.

İ., SAYINALP N., HAZNEDAROĞLU İ. C., et al.

15. INTERNATIONAL HEMOPHILIA CONGRESS OF TURKEY, İstanbul, Turkey, 4 - 07 April 2018

XXXIV. DAMAK TUTULUMU İLE EKSTRAMEDÜLLER NÜKS OLAN RELAPS REFRAKTER MULTİPLE MYELOM OLGUSU

ÇİFTÇİLER R., OKAY M., ALADAĞ KARAKULAK E., DEMİROĞLU H., GÖKER H.

3. ULUSAL KAN VE KEMİK İLİĞİ NAKLİ KONGRESİ, Cyprus (Kktc), 29 - 31 March 2018

XXXV. Prognosis of Multiple Myeloma in Younger Patients Who Are Undergoing Upfront Autologous Stem Cell Transplantation

KELKİTLİ E., GÖKER H., DEMİROĞLU H., TURGUT M., OKAY M., SAYINALP N., AKSU S., HAZNEDAROĞLU İ. C., AYDIN M. S., tekin f., et al.

LYMPHOMA AND MYELOMA 2017, New York, United States Of America, 26 - 28 November 2017, vol.1, pp.43-44

XXXVI. Donor Lymphocyte Infusions: Single Center Experience

KELKİTLİ E., GÖKER H., TURGUT M., DEMİROĞLU H., SAYINALP N., AKSU S., HAZNEDAROĞLU İ. C., OKAY M., AYDIN M. S., tekin f., et al.

LYMPHOMAMYELOMA 2017, New York, United States Of America, 26 - 28 November 2017, vol.1, pp.48

XXXVII. Prognosis of Multiple Myeloma in Younger Patients who Undergoing Upfront Autologous Stem Cell Transplantation

KELKİTLİ E., GÖKER H., demiroglu H., TURGUT M., SAYINALP N., AKSU S., HAZNEDAROĞLU İ. C., Aydın S., Tekin F., BÜYÜKAŞIK Y.

LYMPHOMA MYELOMA 2017, 26 - 28 October 2017

XXXVIII. Donor Lymphocyte Infusion: Single Center Experience

KELKİTLİ E., GÖKER H., TURGUT M., Demiroğlu H., SAYINALP N., AKSU S., HAZNEDAROĞLU İ. C., OKAY M., Aydın S., Tekin F., et al.

LYMHOMA MYELOMA 2017, 26 - 28 October 2017

XXXIX. EFFECT OF INDUCTION THERAPY ON SURVIVAL IN MULTIPLE MYELOMA PATIENTS

DEMİROĞLU H., ALADAĞ KARAKULAK E., AKSU S., BÜYÜKAŞIK Y., HAZNEDAROĞLU İ. C., SAYINALP N., ÖZCEBE O. İ., GÖKER H.

INTERNATIONAL CONGRESS OF BMT 2018, Busan, South Korea, 30 August - 01 September 2018, vol.53

XL. Kemoterapiye refrakter primer mediastinal granülositik sarkom hastasının allojeneik kök hücre transplantasyonu ile tedavisi

ETGÜL S., MALKAN Ü. Y., TURGUT M., DEMİROĞLU H., BÜYÜKAŞIK Y., HAZNEDAROĞLU İ. C., GÖKER H.

2. Hematolojik Onkoloji Kongresi, Cyprus (Kktc), 16 - 19 February 2017

XLI. Determination of chemoterapoetic drugsensitivity subgroups of acute leukemia

Türk S., Ghasemi M., malkan Ü. Y., ERİKÇİ A., GÖKER H., HAZNEDAROĞLU İ. C., GÜRE A. O., UÇAR G.

The FEBS Journal, 3 - 08 September 2016

XLII. Determination of chemoterapoetic drug sensitivity subgroups of acute leukemia

TÜRK S., Ghasemi M., MALKAN Ü. Y., Erikci A., GÖKER H., SAYINALP N., HAZNEDAROĞLU İ. C., Gure A. O., UÇAR G.

41st FEBS Congress on Molecular and Systems Biology for a Better Life, Kusadasi, Turkey, 3 - 08 September 2016, vol.283, pp.373-374

XLIII. A LATE-ONSET ACUTE GRAFT VERSUS HOST DISEASE CASE WHO IS RESISTANT TO BOTH TACROLIMUS AND CYCLOSPORINE

Malkan Ü. Y., GÜNEŞ G., Aslan T., AKSU S., GÖKER H., HAZNEDAROĞLU İ. C.

6th International Eurasian Hematology Congress, Antalya, Turkey, 14 - 18 October 2015, vol.39

XLIV. AN IGD MYELOMA CASE THAT IS RESISTANT TO CARFILZOMIB

Malkan Ü. Y., GÜNEŞ G., ETGÜL S., HAZNEDAROĞLU İ. C., DEMİROĞLU H., GÖKER H.

6th International Eurasian Hematology Congress, Antalya, Turkey, 14 - 18 October 2015, vol.39

XLV. SUCCESSFUL TREATMENT OF RESISTANT CHRONIC GRAFT VERSUS HOST DISEASE WITH EXTRACORPOREAL PHOTOPHERESIS IN A PAROXYSMAL NOCTURNAL HEMOGLOBINURIA PATIENT WHO HAS UNDERGONE ALLOGENEIC STEM CELL TRANSPLANTATION

Malkan Ü. Y., GÜNEŞ G., ELİAÇIK E., Yayar O., GÖKER H., ÖZCEBE O. İ.

6th International Eurasian Hematology Congress, Antalya, Turkey, 14 - 18 October 2015, vol.39

- XLVI. A COMPOSITE LYMPHOMA CASE**
Malkan Ü. Y., GÜNEŞ G., Yayar O., DEMİROĞLU H., GÖKER H., HAZNEDAROĞLU İ. C.
6th International Eurasian Hematology Congress, Antalya, Turkey, 14 - 18 October 2015, vol.39
- XLVII. GENERIC IMATINIB MESYLATE IS AS EFFECTIVE AS ORIGINAL GLIVEC IN THE MANAGEMENT OF CML**
AKSU S., Aktimur S. H., Arica D. C., Atay H., Bektas O., BÜYÜKAŞIK Y., DEMİROĞLU H., Eliacik E., Esme M., GÖKER H., et al.
20th Congress of European-Hematology-Association, Vienna, Austria, 11 - 14 June 2015, vol.100, pp.690
- XLVIII. Extramedullary relapses after allogeneic stem cell transplantation for leukemia: Clinical characteristics, cumulative incidence and risk factors**
Goker H., Gunes G., Demiroglu H., Malkan Ü. Y., Haznedaroglu I., Sayinalp N., Etgul S., Eliacik E., Aslan T., Isik A., et al.
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, Illinois, United States Of America, 29 May - 02 June 2015, vol.33
- XLIX. Lower Doses of Plerixafor Use Is Sufficient to Effectively Mobilize PBSC (Peripheral Blood Hematopoetic Stem Cells) When Compared to Standard Administration**
GÖKER H., ELİAÇIK E., Altuntas F., Tekgunduz E., ÖZDEMİR E., Isik A., Kayikci O., Kaya A. H., AKSU S., HAZNEDAROĞLU İ. C., et al.
56th Annual Meeting of the American-Society-of-Hematology, San-Francisco, Costa Rica, 6 - 09 December 2014, vol.124
- L. Evaluation of Anti-Neoplastic Effects of a New Hemostatic Agent Ankaferd Blood Stopper on Myeloma Cell Line and Plasmocytoma Development in Balb/c Mice: Results of the First in Vitro and in Vivo Study**
Avcu F., Guner M., Misirci M., Elci P., Safali M., GÖKER H., HAZNEDAROĞLU İ. C.
56th Annual Meeting of the American-Society-of-Hematology, San-Francisco, Costa Rica, 6 - 09 December 2014, vol.124
- LI. Prognostic Factors for Survival of Elderly Patients with Acute Myeloid Leukemia after Intensive Chemotherapy: Validation of 3 Popular Prognostic Models**
Koca E., Halacoglu A., Malkan Ü. Y., Arica D., Karakus S., GÖKER H., HAZNEDAROĞLU İ. C., SAYINALP N., BÜYÜKAŞIK Y.
56th Annual Meeting of the American-Society-of-Hematology, San-Francisco, Costa Rica, 6 - 09 December 2014, vol.124
- LII. GENERIC IMATINIB MESYLATE IS AS EFFECTIVE AS ORIGINAL GLIVEC IN THE MANAGEMENT OF CML**
AKSU S., AKTİMUR S., ARİCA D., ATAY M. H., BEKTAŞ Ö., BÜYÜKAŞIK Y., DEMİROĞLU H., ELİAÇIK E., EŞME M., GÖKER H., et al.
20th Congress of the European Hematology Association Vienna, Austria June 11-14,2015, 11 - 14 June 2014
- LIII. High-dose chemotherapy and autologous peripheral blood stem cell (PBSC) transplantation with in vitro cryopreserved PBSCs in multiple myeloma**
Goker H., Eliacik E., Buyukasik Y., Haznedaroglu I. C., Turgut M., Aksu S., Sayinalp N., Gunes G., Laemirogiu H., Ozcabe O. I.
50th Annual Meeting of the American-Society-of-Clinical-Oncology, Illinois, United States Of America, 30 May - 03 June 2014, vol.32
- LIV. Philadelphia-positive acute lymphoblastic leukemia in daily practice: A multicenter experience.**
Goker H., Tekgunduz E., Sari I., Pala C., Dogu M. H., Ozturk E., Turgut B., Korkmaz S., Demiriz I. S., Buyukasik Y., et al.
49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 31 May - 04 June 2013, vol.31
- LV. Laser methods for pharmaceutical pollutants removal**
Smarandache A., Militaru A., GÖKER H., Pascu A., Pascu M.
6th Conference on Advanced Topics in Optoelectronics, Microelectronics, and Nanotechnologies (ATOM-N), Constanta, Romania, 23 - 26 August 2012, vol.8411
- LVI. Serological response to influenza vaccine haematopoetic stem cell transplantation patients**
YALÇIN Ş., Kondolot M., Albayrak N., Altas B., Karacan Y., KUŞKONMAZ B. B., AKSU S., ÇETİN M., GÖKER H.,

YURDAKÖK K., et al.

36th Annual Meeting of the European-Group-for-Blood-and-Marrow-Transplantat/9th Meeting of the EBMT Data-Management-Group/26th Meeting of the EBMT Nurses Group/2nd EBMT Qual Management Meeting, Vienna, Austria, 21 - 24 March 2010, vol.45

- LVII. Comparison of Low Dose Total Body Irradiation (TBI)-Based Reduced Intensity Conditioning (RIC) Vs. Chemotherapy-Based RIC Prior to Allogeneic Stem Cell Transplantation (allo-SCT) From An HLA Identical Sibling Donor for Acute Myeloid Leukemia (AML) in First Complete Remission (CR1): a Retrospective Analysis of 1200 Patients From the Acute Leukemia Working Party of EBMT.**
Mohty M., Labopin M., Janssen J. J. W. M., Mufti G. J., Cornelissen J. J., Milpied N., Sengeloev H., Blaise D., Petersen E., GÖKER H., et al.
51st Annual Meeting of the American-Society-of-Hematology, Louisiana, United States Of America, 5 - 08 December 2009, vol.114, pp.489
- LVIII. Addition of Thalidomide (T) to Oral Melphalan/Prednisone (MP) in Patients with Multiple Myeloma: Initial Results of a Randomized Trial From the Turkish Myeloma Study Group.**
BEKSAÇ M., HAZNEDAR R., Firatli-Tuglular T., Ozdogu H., Aydogdu I., Konuk N., Sucak G., Kaygusuz I., Karakus S., KAYA E., et al.
51st Annual Meeting of the American-Society-of-Hematology, Louisiana, United States Of America, 5 - 08 December 2009, vol.114, pp.746-747
- LIX. Impact of Cytogenetics Risk on Outcome after Reduced Intensity Conditioning (RIC) Allogeneic Stem Cell Transplantation (allo-SCT) from An HLA Identical Sibling for Patients with Acute Myeloid Leukemia (AML) in First Complete Remission (CR1)**
Mohty M., Labopin M., Milpied N., Cornelissen J. J., Blaise D., Petersen E., Theorin N., GÖKER H., Socie G., Rocha V.
50th Annual Meeting of the American-Society-of-Hematology, San-Francisco, Costa Rica, 6 - 09 December 2008, vol.112, pp.134-135
- LX. Haemostatic actions of the folkloric medicinal plant extract, Ankaferd Blood Stopper**
GÖKER H., HAZNEDAROĞLU İ. C., Ercetin S., Kirazli S., Akman U., Ozturk Y., Firat C. H.
49th Annual Meeting of the American-Society-of-Hematology, Georgia, United States Of America, 8 - 11 December 2007, vol.110

Metrics

Publication: 217

Citation (WoS): 1216

Citation (Scopus): 703

H-Index (WoS): 17

H-Index (Scopus): 13